Selecta Biosciences, which is developing immunotherapies based on its proprietary nanoparticle platform, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering.
The Watertown, MA-based company was founded in 2007 and plans to list on the Nasdaq under the symbol SELB. Selecta Biosciences filed confidentially on November 24, 2015. UBS Investment Bank and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
